Orforglipron is a new oral drug for type 2 diabetes that belongs to the group of GLP-1 receptor agonists[1]. The ACHIEVE-3 trial compared its effectiveness with oral semaglutide in patients with type 2 diabetes who had inadequate blood sugar control despite taking metformin[1]. Orforglipron at doses of 12 mg and 36 mg was non-inferior and even superior to semaglutide at doses of 7 mg and 14 mg in reducing HbA1c (an indicator of long-term blood sugar control) over 52 weeks of treatment[1]. The drug works by improving insulin secretion and reducing the amount of glucose produced by the liver, thereby stabilizing blood sugar levels[1]. The safety profile of both drugs was similar and corresponded to the safety of the group of GLP-1 receptor agonists[1]. However, orforglipron had a higher incidence of gastrointestinal events, more patients discontinued treatment due to adverse effects, and caused a greater increase in pulse rate compared to oral semaglutide[1].